Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Chidamide is an inhibitor of histone deacetylases (HDACs; IC50s = 0.095, 0.160, 0.067, 0.733, 0.078, and 0.432 µM for HDAC1-3, 8, 10, and 11, respectively).1 It is selective for these HDACs over HDAC4-7 and 9 (IC50s = >30 µM for all). Chidamide also inhibits nicotinamide phosphoribosyltransferase (Nampt; IC50 = 2.1 µM).2 It inhibits cell growth in a panel of 18 cancer cell lines (GI50s = 0.4-40 µM) but has no effect on the growth of non-cancerous CCC-HEK human fetal kidney or CCC-HEL human liver cells (GI50s = >100 µM).1 In vivo, tucidinostat (12.5, 25, and 50 mg/kg) reduces tumor growth in HCT-8, A549, BEL-7402, and MCF-7 mouse xenograft models.1
WARNING This product is not for human or veterinary use.
1. Chidamide (CS055/HBI-
2. Nicotinamide phosphoribosyltransferase (NAMPT) is a new target of antitumor agent chidamide. ACS Med. Chem. Lett. 11(1), 40-44 (2020).